ZURICH/BERLIN, May 28 (Reuters) - The Swiss blue-chip SMI was seen opening 0.2 percent higher at 9,736 points on Tuesday, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks:
Swiss-listed drugmaker Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug Administration raised concerns about central nervous system events that have emerged in rats and dogs.
* Burckhardt Compression Holding AG: FY Consolidated net income amounted to CHF 32.2 mn, 10.9% more than in the previous fiscal year; expects to report a slight increase in 2019 profit margins; proposes unchanged dividend of CHF 6.00 per share
* Dottikon Es Holding AG: FY net income was CHF 16.3 million (previous year: 25.8 million); for ongoing full business year 2019/20, dottikon expects net sales above previous year
* Sika is starting operations at a plant in Doha, Qatar, for the production of concrete admixtures
Swiss Q1 GDP growth accelerated to 0.6% versus previous quarter. Market had expected 0.4% growth.
Swiss April trade surplus 2.3 bln francs, watch exports ease 0.4% in nominal terms
Reporting by Zurich newsroom and Berlin Speed Desk